Description
Inrebic (fedratinib) is a medication used to treat myelofibrosis, a rare blood cancer that develops when abnormal cells accumulate in the bone marrow. Inrebic is an oral medication that works by inhibiting the activity of a protein called JAK2 that is involved in the growth and survival of abnormal cells in the bone marrow.
Uses:
Inrebic is used to treat myelofibrosis in adult patients who have intermediate-2 or high-risk disease. The medication can improve symptoms such as fatigue, night sweats, and enlarged spleen.
Storage Conditions:
Inrebic should be stored at room temperature between 68°F to 77°F (20°C to 25°C). The medication should be kept in the original container with the cap tightly closed and should be protected from excessive heat and moisture.
Mechanism of Action:
Inrebic works by inhibiting the activity of a protein called JAK2, which is involved in the growth and survival of abnormal cells in the bone marrow. By blocking the activity of JAK2, Inrebic helps to reduce the production of abnormal cells and the progression of myelofibrosis.
HOW TO USE:
Inrebic is taken orally either with or without food, as directed by the healthcare provider. The medication is available in capsule form and should be swallowed whole with water. Patients should never chew or crush Inrebic capsules. The dosage of Inrebic is based on the patient’s weight, medical condition, and response to treatment.
Precautions:
• It is important to inform the healthcare provider of all medications, supplements, or herbal products the patient is taking before starting treatment with Inrebic.
• Patients with liver disease or a history of liver problems should use Inrebic with caution.
• Patients should be monitored for symptoms of anemia, bleeding, or infection during treatment with Inrebic.
• The use of Inrebic in pregnant women is not recommended.
Drug Interactions:
Inrebic may interact with certain medications, including CYP3A4 inhibitors, such as clarithromycin, ketoconazole, and grapefruit juice, which can increase the levels of Inrebic in the bloodstream and cause adverse effects. Patients should inform their healthcare provider of all medications, supplements, or herbal products they are taking before starting treatment with Inrebic.
Contraindications:
• Inrebic should not be used in patients with a known hypersensitivity to the medication or to any of its components.
• The medication is also contraindicated in patients with severe liver disease or liver failure.
Overdose:
In case of an overdose, the patient should contact a healthcare provider immediately. Symptoms of an overdose are not known, as high doses of Inrebic have not been studied.
Adverse Reactions:
Common adverse reactions associated with the use of Inrebic include anemia, diarrhea, fatigue, and increased blood pressure. Patients should contact their healthcare provider if they experience any unusual reactions while using Inrebic.
In conclusion, Inrebic (fedratinib) is an oral medication used to treat myelofibrosis by inhibiting the activity of the JAK2 protein. The medication is available in capsule form and should be taken orally as directed by the healthcare provider. Inrebic is stored at room temperature and should be kept in the original container with the cap tightly closed. Patients should be cautious and inform their healthcare provider of any liver problems or the use of other medication, supplements, or herbal products before using Inrebic. The medication has several contraindications, drug interactions, and precautions to be considered before consumption. Common adverse reactions are anemia, diarrhea, fatigue, and increased blood pressure.
Reviews
There are no reviews yet.